Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.00−0.08 (-0.44%)
Close on Nov 17, 2026Market cap $2.88BP/E –Yield –
Denali Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Denali Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2025 it was $0. The highest annual figure on record is $335.66M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $330.53M | +204.7% |
| FY2022 | Dec 31, 2022 | $108.46M | +122.9% |
| FY2021 | Dec 31, 2021 | $48.66M | -85.5% |
| FY2020 | Dec 31, 2020 | $335.66M | +1158.2% |
| FY2019 | Dec 31, 2019 | $26.68M | -79.3% |
| FY2018 | Dec 31, 2018 | $129.16M | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.60M | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.27M | -64.4% |
| Q2 FY2023 | Jun 30, 2023 | $294.12M | +460.4% |
| Q1 FY2023 | Mar 31, 2023 | $35.14M | -16.6% |
| Q4 FY2022 | Dec 31, 2022 | $10.28M | -17.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.56M | -32.7% |
| Q2 FY2022 | Jun 30, 2022 | $52.48M | +128.8% |
| Q1 FY2022 | Mar 31, 2022 | $42.14M | +431.9% |
| Q4 FY2021 | Dec 31, 2021 | $12.51M | -96.1% |
| Q3 FY2021 | Sep 30, 2021 | $5.29M | -43.7% |
| Q2 FY2021 | Jun 30, 2021 | $22.94M | +292.3% |
| Q1 FY2021 | Mar 31, 2021 | $7.92M | +119.8% |
| Q4 FY2020 | Dec 31, 2020 | $316.82M | +6681.1% |
| Q3 FY2020 | Sep 30, 2020 | $9.39M | -31.0% |
| Q2 FY2020 | Jun 30, 2020 | $5.85M | +39.3% |
| Q1 FY2020 | Mar 31, 2020 | $3.60M | -14.3% |
| Q4 FY2019 | Dec 31, 2019 | $4.67M | -96.3% |
| Q3 FY2019 | Sep 30, 2019 | $13.60M | +1038.4% |
| Q2 FY2019 | Jun 30, 2019 | $4.20M | +154.7% |
| Q1 FY2019 | Mar 31, 2019 | $4.21M | +556.0% |
| Q4 FY2018 | Dec 31, 2018 | $125.68M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.20M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.65M | – |
| Q1 FY2018 | Mar 31, 2018 | $641.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
See a number that looks wrong?